Astellas Pharma Inc. Logo

Astellas Pharma Inc.

A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.

4503 | T

Overview

Corporate Details

ISIN(s):
JP3942400007
LEI:
Country:
Japan
Address:
中央区日本橋本町二丁目5番1号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Astellas Pharma Inc. is a global pharmaceutical company dedicated to improving human health by turning innovative science into value for patients. Formed in 2005 from the merger of Yamanouchi Pharmaceutical Co. and Fujisawa Pharmaceutical Co., the company engages in the research, development, manufacturing, and marketing of innovative pharmaceutical products. Astellas focuses on addressing unmet medical needs in several therapeutic areas, with a primary emphasis on oncology. Its key areas of innovation also include gene therapy, immuno-oncology, regenerative medicine, and treatments for blindness and mitochondrial diseases. The company is committed to a stable supply of reliable medicines worldwide and stands at the forefront of healthcare change.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-06 03:29
Report Publication Announcement
確認書
Japanese 8.9 KB
2025-11-06 03:26
Interim Report
半期報告書-第21期(2025/04/01-2026/03/31)
Japanese 310.0 KB
2025-07-31 08:30
Registration Form
訂正発行登録書
Japanese 9.7 KB
2025-07-31 04:04
Post-Annual General Meeting Information
訂正臨時報告書
Japanese 33.0 KB
2025-07-03 08:31
Registration Form
訂正発行登録書
Japanese 10.3 KB
2025-07-02 02:28
Post-Annual General Meeting Information
臨時報告書
Japanese 24.1 KB
2025-06-16 06:14
Governance Information
内部統制報告書-第20期(2024/04/01-2025/03/31)
Japanese 23.1 KB
2025-06-16 06:11
Registration Form
確認書
Japanese 8.7 KB
2025-06-16 06:09
Annual Report
有価証券報告書-第20期(2024/04/01-2025/03/31)
Japanese 2.5 MB
2025-02-04 07:47
Registration Form
訂正発行登録書
Japanese 9.9 KB
2025-02-04 07:40
Regulatory News Service
臨時報告書
Japanese 19.4 KB
2025-02-04 07:39
Regulatory News Service
臨時報告書
Japanese 20.9 KB
2024-11-06 05:52
Interim Report
確認書
Japanese 8.9 KB
2024-11-06 05:51
Interim Report
半期報告書-第20期(2024/04/01-2025/03/31)
Japanese 344.2 KB
2024-09-03 03:34
Registration Form
発行登録追補書類(株券、社債券等)
Japanese 96.0 KB

Automate Your Workflow. Get a real-time feed of all Astellas Pharma Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Astellas Pharma Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Astellas Pharma Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.